India Based Pharma Companies In Race To Buy Athenex, Shares Surge
India Based Pharma Companies In Race To Buy Athenex, Shares Surge
總部位於印度的製藥公司競逐購買 Athenex，股票激增
- Athenex Inc (NASDAQ:ATNX) shares climbed during the after-hours session as India's Intas Pharmaceuticals and Dr Reddy's Laboratories Ltd (NYSE:RDY) are reportedly in talks to acquire Athenex.
- According to the Economic Times report, the deal could be valued at $200-250 million as the U.S.-based biotechnology firm looks to sell a controlling stake.
- The two Indian pharma companies are competing with a handful of mid-market healthcare-focused private equity funds in the US, people with knowledge of the matter told ET.
- Athenex had hired investment advisory firm Cowen Inc to run a formal process to find a buyer.
- "A formal process has started, and the first round of offers have come in," said one of the people. "Intas and Dr Reddy's are the two Indian firms in the race. A transaction could be concluded during the current quarter."
- During its recent earnings release, Athenex reported Q2 product sales of $25.8 million, +26% Y/Y.
- It is said to have raised $85 million in total transaction value in Q2 for a total of $125 million in proceeds from sales of non-core assets in 1H 2022.
- It maintains the FY22 product revenue guidance range of 20-25% growth Y/Y.
- Price Action: ATNX shares closed 69.9% higher at $1.07 during after-hours trading on Thursday.
- Athenex Inc (NASDAQ:ATNX) shares climbed during the after-hours session as India's Intas Pharmaceuticals and Dr Reddy's Laboratories Ltd (NYSE:RDY) are reportedly in talks to acquire Athenex.
- According to the Economic Times report, the deal could be valued at $200-250 million as the U.S.-based biotechnology firm looks to sell a controlling stake.
- The two Indian pharma companies are competing with a handful of mid-market healthcare-focused private equity funds in the US, people with knowledge of the matter told ET.
- Athenex had hired investment advisory firm Cowen Inc to run a formal process to find a buyer.
- "A formal process has started, and the first round of offers have come in," said one of the people. "Intas and Dr Reddy's are the two Indian firms in the race. A transaction could be concluded during the current quarter."
- During its recent earnings release, Athenex reported Q2 product sales of $25.8 million, +26% Y/Y.
- It is said to have raised $85 million in total transaction value in Q2 for a total of $125 million in proceeds from sales of non-core assets in 1H 2022.
- It maintains the FY22 product revenue guidance range of 20-25% growth Y/Y.
- Price Action: ATNX shares closed 69.9% higher at $1.07 during after-hours trading on Thursday.
- 雅典娜納斯達克：ATNX）股票在下班後的會議期間攀升為印度的股票印塔斯制药和雷迪博士實驗室有限公司紐約證券交易所代碼：RDY）據報導正在談判收購雅典娜。
- 根據《經濟時報》報告，這筆交易的價值可能為 200-2.5 億美元，因為這家總部位於美國的生物技術公司期望出售控股權。
- 這兩家印度製藥公司正在與美國少數以醫療保健為中心的私募股權基金競爭，對此事有知識的人告訴 ET。
- 雅典娜聘請了投資顧問公司 Cowen Inc. 運行正式的流程來尋找買家。
- 其中一位人士說：「正式的過程已經開始，第一輪優惠已經進入。「印達斯和雷迪博士是比賽中的兩家印度公司。交易可以在本季度完成。」
- 在最近的盈利發布期間，雅典娜公佈第二季度的產品銷售額為 25.8 百萬美元，按年增長 26％。
- 據說在第二季度籌集了 8,500 萬美元的交易總額，作為 2022 年上半年銷售非核心資產的收益總額 1.25 億美元。
- 該公司維持 22 財年產品營收指引範圍在 20-25% 的年增長率。
- 價格行動：ATNX 股票於周四收市後交易時段收市後收市收市 69.9%，報 1.07 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！